Rigel Pharmaceuticals (RIGL) Gross Profit (2018 - 2026)

Rigel Pharmaceuticals' Gross Profit history runs 9 years deep, the most recent figure standing at $54.2 million for Q1 2026.

• In Q1 2026, Gross Profit rose 10.81% year-over-year to $54.2 million; the TTM figure through Mar 2026 stood at $279.9 million (up 53.78% YoY), while the FY2025 annual figure was $274.7 million, up 70.99% from the prior year.
• Gross Profit was $54.2 million for Q1 2026 at Rigel Pharmaceuticals, down from $63.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $97.2 million in Q2 2025 to a low of $16.6 million in Q1 2022.
• Historically, Gross Profit has averaged $42.2 million across 5 years, with a median of $34.0 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Gross Profit plunged 79.41% in 2022, then jumped 185.54% in 2025.
• A 5-year view of Gross Profit shows it stood at $50.9 million in 2022, then plunged by 37.17% to $32.0 million in 2023, then soared by 61.89% to $51.8 million in 2024, then increased by 23.24% to $63.8 million in 2025, then fell by 15.09% to $54.2 million in 2026.
• The last three Gross Profit figures came in at $54.2 million (Q1 2026), $63.8 million (Q4 2025), and $64.7 million (Q3 2025), per Business Quant data.